Leciva Praha, the largest producer of pharmaceuticals in the Czech Republic, is expected to achieve a profit of 850 million crowns ($30.3 million) on a turnover of 4 billion crowns in 1994, according to the CTK news agency's Business News.
Leciva, which has a domestic market share of 21%, produces around 180 preparations in 250 medicinal forms. Mainly known for its antibiotic, ampicillin, and flu remedy Paralen, the company sells more than 70% of its production on the Czech market, while 20% is exported to Slovakia and 10% to Western countries. A third of production is accounted for by licensed preparations from international pharmaceutical companies such as Sandoz and Roussel Uclaf.
The company has invested more than 1 billion crowns over the past three years in its modernization. It employs a workforce of 1,480.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze